BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 17172368)

  • 1. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
    Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report.
    Zerpa O; Blanco B; Kannee C; Ulrich M; Sindermann H; Engel J; Convit J
    Int J Dermatol; 2006 Jun; 45(6):751-3. PubMed ID: 16796642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
    Zerpa O; Ulrich M; Blanco B; Polegre M; Avila A; Matos N; Mendoza I; Pratlong F; Ravel C; Convit J
    Br J Dermatol; 2007 Jun; 156(6):1328-35. PubMed ID: 17441955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo activity of perifosine against Leishmania amazonensis.
    Cabrera-Serra MG; Valladares B; Piñero JE
    Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
    Stojkovic M; Junghanss T; Krause E; Davidson RN
    Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Miltefosine: a new remedy for leishmaniasis].
    Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of a married couple for American leishmaniasis with miltefosine.
    Wöhrl S; Schnedl J; Auer H; Walochnik J; Stingl G; Geusau A
    J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):258-9. PubMed ID: 18211436
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of New World cutaneous leishmaniasis with miltefosine.
    Soto J; Berman J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.
    Ordaz-Farias A; Muñoz-Garza FZ; Sevilla-Gonzalez FK; Arana-Guajardo A; Ocampo-Candiani J; Treviño-Garza N; Becker I; Camacho-Ortiz A
    Am J Trop Med Hyg; 2013 Jan; 88(1):153-6. PubMed ID: 23243111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
    Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
    Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Miltefosine for disseminated cutaneous leishmaniasis].
    González LM; Vélez ID
    Biomedica; 2006 Oct; 26 Suppl 1():13-6. PubMed ID: 17361837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
    Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
    Schraner C; Hasse B; Hasse U; Baumann D; Faeh A; Burg G; Grimm F; Mathis A; Weber R; Günthard HF
    Clin Infect Dis; 2005 Jun; 40(12):e120-4. PubMed ID: 15909255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
    Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.